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Gene transfer into a panel of non-small cell lung cancer (NSCLC) cells by adenoviral (Ad) and retroviral
(RV) vectors was studied. Indexed to multiplicity of infection (MOI), Ad vectors transduce squamous, ad-
enosquamous, and malignant mesothelioma cells with greater efficiency than large cells or adenocarci-
noma cells. Transduction-sensitive cells bind the Ad vector with specificity for the Ad fiber knob, and in-
ternalize vector efficiently. Transduction-refractory cells bind and internalize vector by less efficient
pathways. Like Ad vectors, there is heterogeneity in RV transduction efficiencies of different NSCLC sub-
types. With respect to the most common cell type metastatic to the pleural space (adenocarcinoma), am-
photropic retroviral vectors transduce cells of this subtype more efficiently (at a lower MOI) than Ad. RV
transduction is not solely dependent on cellular replication, and both permissive and refractory cell lines
express the mRNA for the amphotropic RV receptor. These observations suggest that neither Ad nor RV
vectors will suffice 
 
a priori
 
 as the optimal gene transfer vehicle, and successful gene therapy of lung can-
cer may require tumor-specific or patient-specific vectors. 
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Lung cancer is the leading cause of cancer mortality in the
United States. Despite gains in survival and quality of life
using conventional multimodality (chemotherapy, radia-
tion, and surgery) approaches, this disease results in 160,000
deaths annually. As a result, newer biologic therapeutic
strategies, including gene therapy, are being developed.
Among these, tumor-suppressor gene replacement ther-
apy (1), immunomodulatory and genetic vaccination strat-
egies (2–4), drug-sensitizing or “suicide gene” therapy (5,
6), and antisense therapy targeting oncogene products (7,
8) are examples of proposed conceptual approaches. Irre-
spective of the paradigm, it is likely that efficient gene
transfer into target cells 
 
in vivo
 
 will be required for the
successful gene therapy of lung cancer. The target cells in
many of the approaches are tumor cells, and given the var-
ious cellular subtypes that comprise lung cancer, it is un-
clear whether a single vector will suffice for gene delivery.
To date, gene transfer is most efficient using viral vec-
tors, and two such vectors are commonly associated with
humans. The adenoviral vector is a transient expression
system that can be generated at high titer (9), and on the
basis of previous reports is promiscuous for targeting a va-
riety of cell types (10). The general steps mediating ade-
noviral transduction are: (
 
1
 
) binding with high affinity to a
specific cell surface receptor (11, 12); (
 
2
 
) receptor-medi-
ated endocytosis into the target cell mediated in part by
specific cell surface integrins (13, 14); (
 
3
 
) endosomal es-
cape and intracellular transport to the nuclear pore (15,
16); and (
 
4
 
) episomal expression of the vector DNA. The
retroviral (RV) vector is integrative and can be generated
only in lower titers. The general steps mediating ampho-
tropic retroviral transduction are characterized as: (
 
1
 
)
binding of a viral envelope glycoprotein specifically to a
target cell receptor (17, 18); (
 
2
 
) fusion of the virus with the
target cell plasma membrane; (
 
3
 
) reverse transcription and
 
(
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b
 
-
 
D
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m
 
g/ml streptomycin, M
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dium with 10% fetal bovine serum, 100 U/ml penicillin, and 100 
 
m
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roviral, RV; sodium dodecyl sulfate, SDS; standard error of the mean,
SEM; saline sodium citrate, SSC.
 
 Batra, Olsen, Pickles, 
 
et al.
 
: Gene Transfer to Non-Small Cell Lung Cancer Cells 403
transport of the vector DNA to the nucleus during disas-
sembly in mitosis; and (
 
4
 
) proviral integration and trans-
gene expression (19). Because the latter steps for RV
transduction require cellular turnover (20), the Moloney
murine leukemia virus (Mo-MuLV)-based RV system may
potentially enable targeting specificity for cancer cells (i.e.,
replicating cells) in selected systems (e.g., brain tumors).
We have chosen malignant pleural effusions as a “proof-
of-concept” clinical model, and hypothesize that principles
of vector targeting in this model may have implications for
the treatment of lung cancer in general. These preclinical
studies were designed to identify the most efficient vector
for targeting various non-small cell lung cancer (NSCLC)
cells in the pleural space, and focused on comparing aden-
oviral (Ad) and RV vectors in 
 
in vitro
 
 studies. Therefore,
the cell lines used for these studies were primarily derived
from the pleural space to model the relevant target cell pop-
ulation. To compare the relative efficiency of gene transfer
vectors, we indexed transduction (as measured by reporter
gene expression) to multiplicity of infection (MOI, num-
ber of infectious particles per target cell). In addition, al-
though all histopathologic subtypes can lead to malignant
pleural effusions, they result most commonly from lung ad-
enocarcinoma metastatic to the pleural space (21). There-
fore, particular attention was given to the vector-mediated
transduction of this NSCLC subtype. Finally, because of the
observed differences in vector-specific transduction of dif-
ferent NSCLC subtypes, an evaluation of the underlying
mechanisms affecting transduction efficiency by both the
adenoviral and retroviral vectors was performed.
 
Materials and Methods
 
Cell Lines
 
Cell lines were a gift of Dr. Herbert Oie at the National
Cancer Institute (NCI), and were maintained in RPMI
1640 (GIBCO-BRL, Gaithersburg, MD) with 10% fetal
bovine serum (GIBCO-BRL) and penicillin (100 U/ml)–
streptomycin (100 
 
m
 
g/ml) (R
 
10
 
; GIBCO-BRL). Many of
these cell lines were described with respect to their mor-
phologic and genetic profile by Dr. Adi Gazdar and col-
leagues (22–25), and detailed characteristics of all lines is
provided in the NCI-Navy Medical Oncology Branch Cell
Line Data Base (26). To target the appropriate cells 
 
in
vitro
 
, a panel of NSCLC subtypes derived from the pleural
space and representing a broad spectrum of lung cancer
and mesothelial malignancy (NCI-H28, NCI-H226, NCI-
H460, NCI-H647, and NCI-H1437) was initially studied.
Because the majority of intrapleural metastases arise from
lung adenocarcinoma, a panel representing this specific
NSCLC subtype (NCI-H441, NCI-H1650, NCI-H1666,
and NCI-H2122) was investigated in greater detail. To as-
sess the generalizability of the observed differential trans-
duction, studies were also performed on a different set of
squamous cell cancer cell lines (NCI-H157 and NCI-H1703).
Mv1Lu cells, a lung epithelial cell line easily infectable
with retroviruses, were obtained from the American Type
Cell Culture (ATCC, Rockville, MD) and maintained in
Eagle’s minimal essential medium (MEM) containing 10%
fetal bovine serum and penicillin–streptomycin (M
 
10
 
).
 
Viral Vectors
 
Adenoviral vectors (Ad5CMVLacZ) were constructed in
the Vector Core at the Gene Therapy Center of the Uni-
versity of North Carolina School of Medicine (Chapel Hill,
NC). These adenovirus serotype 5 (Ad5) vectors were E1a/
E1b and partially E3 deleted, and expressed the 
 
Escheri-
chia coli lacZ
 
 gene as the reporter under the regulation of
the cytomegalovirus (CMV) immediate-early promoter
region (27). The adenoviral vector stocks ranged from
1.5 
 
3
 
 10
 
12
 
 to 3 
 
3
 
 10
 
13
 
 particles/ml as measured by optical
density measured at 260 nm (OD
 
260
 
), with titers (derived
from plaque assays of 293 cells) of 1.7 
 
3
 
 10
 
10
 
 and 6.6 
 
3
 
10
 
11
 
 plaque-forming units (pfu)/ml, respectively. 
 
35
 
S-la-
beled Ad5 vectors, produced in the Vector Core at con-
centrations of 
 
z 
 
10
 
12
 
 particles/ml (specific activity, 2–3 
 
3
 
10
 
2
 
3
 
 counts per minute [cpm]/particle), were used to quan-
titate cellular binding and internalization (28). Adenoviral
vectors were purified and concentrated with double CsCl
ultracentrifugation and stored at 
 
2
 
20
 
8
 
C in a nonfreezing
solution containing 25% glycerol, 0.05% bovine serum al-
bumin (BSA), 4 M CsCl, 50 mM NaCl, 0.5 mM MgCl
 
2
 
, and
5 mM Tris-HCl (pH 8). Immediately before use, vectors
were gel-filtered (G-50 Sephadex; Boehringer Mannheim,
Indianapolis, IN) and eluted into R
 
10
 
 medium for trans-
duction studies. Recovery of vector, as measured by absor-
bance at 260 nm (A
 
260
 
 
 
nm
 
) or radiocounts, is reliably 70–
100% using this desalting procedure.
The amphotropic retroviral vector employed in this
study, LNPOZ, was produced using the helper-free cell
line PA.LNPOZ.1 as described (29, 30). LNPOZ vectors
link the neomycin selection marker and the reporter 
 
lacZ
 
gene by a poliovirus internal ribosomal entry site (IRES)
sequence for the generation of a single transcript from the
inserted provirus. Titers were measured by NIH 3T3 trans-
duction assays counting G-418-resistant colonies and gen-
erally ranged from 0.5 
 
3
 
 10
 
6
 
 to 2 
 
3
 
 10
 
6
 
 cfu/ml.
 
Transduction Protocols
 
Twenty-four hours before transduction, 1–2 
 
3
 
 10
 
5
 
 target
cells were seeded into each well of 6-well (3.5-cm) plates
(Costar, Cambridge, MA) with 2 ml of growth medium.
On the day of transduction, the MOI for the vector was
determined by dividing the vector plaque-forming units by
the number of target cells detached (using 1% trypsin–1 mM
EDTA) and counted (using a hemacytometer) from a rep-
resentative well. Serial dilutions (1:10) of the vector were
made in growth medium, and 1-ml aliquots were applied
to each well.
Ad vectors at various MOIs were incubated with the
target cells for 0.75 h at 37
 
8
 
C, 5% CO
 
2
 
, following which the
cells were washed with phosphate-buffered saline (PBS),
growth medium was replaced, and the cells were maintained
at 37
 
8
 
C, 5% CO
 
2
 
 until expression analysis. In subsequent
studies, the adenoviral vector was incubated with target
cells at an MOI of 50 for various time intervals.
As a quality control for different preparations of am-
photropic RV vectors, Mv1Lu cells were included in the
experimental design because these cells exhibited a consis-
tent and predictable infectivity by the RV vectors at MOIs
of 0.1–10. The amphotropic retroviral vectors were incu-
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bated with the target cells in the presence of 8 
 
m
 
g/ml Poly-
brene for 2 h, the vector aspirated, the cells washed with
PBS, growth medium replaced, and the cells maintained at
37
 
8
 
C, 5% CO
 
2
 
 until expression analysis.
 
Transgene Expression Analysis
 
Transduction efficiency was assayed by 
 
lacZ
 
 gene expres-
sion at 24 or 48 h following adenoviral or retroviral trans-
duction, respectively. Histochemical analysis was performed
by assaying for intracellular 5-bromo-4-chloro-3-indoyl-
 
b
 
-
 
D
 
-galactopyranoside (X-Gal; 5 Prime-3 Prime, Boulder,
CO) hydrolysis in fixed (0.5% glutaraldehyde for 10 min,
4
 
8
 
C) target cells (31, 32), and the percentage of positive
cells determined. The expression of 
 
lacZ
 
 was also mea-
sured using flow cytometry (FAC-Scan; Becton Dickin-
son, Mountain View, CA) by surveying 16,000 cells for the
intracellular hydrolysis of fluorescein di-
 
b
 
-
 
D
 
-galactopyra-
noside (FDG; Molecular Probes, Eugene, OR) (33). For
these studies, the target cells were detached, resuspended
in 100 
 
m
 
l of growth medium, exposed to 1 mM FDG in hy-
potonic medium (100 
 
m
 
l of water containing 1.0% dime-
thyl sulfoxide) for 1 min at 37
 
8
 
C, and the substrate loading
stopped with the addition of cold medium containing 1 
 
m
 
g/
ml propidium iodide (PI). Cells that incorporated PI (red
fluorescence) were defined as nonviable and excluded from
analysis at the time of data acquisition. The transduced cell
population constituted those cells exhibiting green fluores-
cence exceeding the 99th percentile of a control popula-
tion that was not transduced with vector but was exposed to
hypotonic shock and FDG loading.
 
Cell Proliferation Analyses
 
To compare the relative proliferative rates of the various
lung cancer cell lines, the cells were pulsed for 2 h with
5-bromo-2
 
9
 
-deoxyuridine (BrdU; Boehringer Mannheim).
After a PBS wash, the cells were fixed in absolute metha-
nol, and the cellular DNA was denatured in 2 N HCl for
2 h at 37
 
8
 
C. Following neutralization with 0.1 M sodium
borate (pH 8.5), the cells were incubated with 50 
 
m
 
g/ml
anti-bromodeoxyuridine fluoroscein conjugate for 1 h. At
least 200 cells per slide were counted in random high-
power fields using fluorescence microscopy, and the per-
centage of labeled (proliferating) cells determined in three
separate experiments.
 
Adenoviral Binding Analyses
 
All binding studies were performed at 4
 
8
 
C using an 
 
35
 
S-
labeled adenoviral vector (
 
35
 
S-Ad5 vector; specific activ-
ity, 1–3 
 
3
 
 10
 
2
 
3
 
 cpm/particle) at a particle-to-cell ratio of
1,000 to 10,000:1. At various time intervals (0, 0.75, 3, 6, 10,
and 30 h), unbound 
 
35
 
S-Ad5 vector was collected in two PBS
washes and radiocounted. Next, the cell-bound fraction
was quantitated by cell lysis (1 ml of 0.3 N NaOH plus 1%
sodium dodecyl sulfate [SDS]: lysis buffer) and 
 
35
 
S radio-
counting. Specific binding to target cells was studied by
competing with 10 
 
m
 
g/ml Ad5 fiber knob (a kind gift from
Dr. Joanne T. Douglas, Gene Therapy Program, Univer-
sity of Alabama, Birmingham), which was coincubated with
the radiolabeled Ad during exposure to target cells (34).
 
Adenoviral Internalization Analyses
 
To determine the kinetics of adenoviral internalization, 5 
 
3
 
10
 
5
 
 target cells were exposed to the 
 
35
 
S-Ad5 vector (particle-
to-cell ratio, 10,000:1) at 37
 
8
 
C, 5% CO
 
2
 
 at time intervals that
paralleled the binding experiments. The unbound fraction
in medium was removed by rinsing cells twice with PBS,
followed by an acid–salt (0.2 M acetic acid in 0.5 M NaCl)
wash and proteinase treatment (0.25% protease XIV at 4
 
8
 
C
for 1 h). The internalized 
 
35
 
S-Ad5 component was collected
by solubilizing the cells in lysis buffer. The efficiency of in-
ternalization of bound vector was calculated by dividing
the internalized counts by the bound counts from parallel
plates at the 0.75-h time interval.
 
RAM-1 Northern Analysis
 
A 481-base pair (bp) fragment of the amphotropic retrovi-
ral receptor (RAM-1) mRNA (bp 794–1,275) was ampli-
fied following reverse transcription (RTth DNA poly-
merase; Perkin-Elmer, Branchburg, NJ) of CFT1 total
cellular RNA (35) harvested using the Trisolv (Biotecx,
Houston, TX) reagent. This fragment was inserted into the
pCRII cloning vector, amplified (TA cloning system; In-
vitrogen, San Diego, CA), and the gel-purified insert was
used to make a 
 
32
 
P-labeled probe using the random primed
DNA-labeling method (Boehringer Manneheim).
Twelve micrograms of total cellular RNA from various
tumor cells in log-phase growth was electrophoresed in a
5% formaldehyde–1.2% agarose gel and transferred onto
a nylon membrane (Stratagene, La Jolla, CA). Northern
hybridization with total cellular RNA was performed us-
ing the RAM-1 probe (activity, 2.7 
 
3
 
 10
 
8
 
 cpm/ml) over-
night at a hybridization temperature of 68
 
8
 
C. Membranes
were washed three times with 2
 
3
 
 saline sodium citrate
(SSC) plus 0.1% SDS at room temperature for 45 min and
once with 0.1
 
3
 
 SSC plus 1% SDS at 60
 
8
 
C for 90 min, ex-
posed to film overnight at 
 
2
 
70
 
8
 
C, and the autoradiogram
developed 24 h later.
 
Statistical Methods
 
Data are reported as the mean 
 
6
 
 the standard error of the
mean, with the overall statistical significance of differences
within the groups determined using Kruskal–Wallis analy-
sis of variance (ANOVA) on ranks, followed by Bonfer-
roni group comparisons (Figure 2). The statistical signifi-
cance of the differences for Ad vector binding and
internalization (Figures 3 and 4) was determined using the
unpaired two-tailed 
 
t
 
 test. Transduction efficiencies of the
adenoviral and retroviral vectors (Figures 1 and 5) were
compared using probit analysis (36). Specifically, the curves
of percent transduction versus MOI (logarithmic values)
were fit for probit analysis using the Statistical Analysis
System (SAS version 6.10; SAS, Cary, NC). This method
provides 95% fiducial intervals (95% FI) for specified
transduction percentages (25% transduction used for all
comparisons). Nonoverlapping fiducial intervals for 25%
transduction efficiency is taken as evidence of a statisti-
cally significant difference (
 
P
 
 
 
,
 
 0.05) between the cell
lines compared.
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Results
 
Figure 1A depicts the range of adenoviral transduction ef-
ficiencies in a variety of histopathologic subtypes of lung
cancer cell lines derived from intrapleural metastases. The
adenoviral vector transduces squamous cell cancer (H226),
adenosquamous (H647), and malignant mesothelioma (H28)
cell lines one to three orders of magnitude lower MOIs than
the adenocarcinoma (H1437) and large cell (H460) cancer
lines. Given these unexpected results, we next tested whether
this differential transduction was generalizable to other
lung squamous cell cancer and adenocarcinoma cell lines.
Three different squamous cell cancers (H157, H226, and
H1703) are all transduced with the adenoviral vectors with
similar efficiency (Figure 1B), and as shown in Figure 1C,
a variety of lung adenocarcinomas (H441, H1437, H1650,
H1666, and H2122) are relatively refractory to adenoviral
transduction when compared to the squamous cell cancers.
Among the group of lung adenocarcinomas, the cell lines
derived from bronchoalveolar cell cancers (H358 [not shown]
and H441; peripheral airway cancers) are the most suscep-
tible, and the H2122 cell line the least susceptible to aden-
oviral transduction. It is noteworthy, however, that all the
adenocarcinoma cell lines can be transduced when exposed
to the adenoviral vector at high (
 
. 
 
100) MOIs (Figure 1C).
We next evaluated the mechanisms that determine the
differences in the adenoviral transduction efficiency of the
squamous cell versus the adenocarcinoma cell lines. Be-
cause differences in adenoviral entry (binding and/or in-
ternalization) may be rate limiting for transduction, we
compared these properties in the permissive squamous
Figure 1. (A) Comparison of adenoviral transduction of NSCLC subtypes or malignant mesothelioma as a function of MOI. Target cells
were exposed to a lacZ adenoviral vector at various MOIs for 45 min, and transduction efficiency (expression of b-galactosidase) mea-
sured 24 h later by flow cytometry. Open circles, H28 (malignant mesothelioma); open squares, H226 (squamous cell carcinoma); open
triangles, H460 (large cell lung cancer); open stars, H647 (adenosquamous lung cancer); solid squares, H1437 (lung adenocarcinoma).
Data are presented as mean 6 SEM of four experiments. (B) Comparison of adenoviral transduction of NSCLC squamous cell lung
cancer cells (open symbols) versus adenocarcinoma (H1437) cells (solid symbols) as a function of MOI. Target cells were exposed to a
lacZ adenoviral vector at various MOIs for 45 min, and transduction efficiency measured 24 h later by histochemistry. Open squares,
H226; inverse open triangles, H157 (squamous cell lung cancer); open half-circles, H1703 (squamous cell carcinomas); solid squares,
H1437 (lung adenocarcinoma). Data are presented as mean 6 SEM of three experiments. (C) Adenoviral transduction of various
NSCLC-adenocarcinoma cells. Target cells were exposed to a lacZ adenoviral vector at various MOIs for 45 min, and transduction effi-
ciency measured 24 h later by flow cytometry. Solid circles, H441 (lung adenocarcinoma); solid squares, H1437 (lung adenocarcinoma);
solid triangles, H1650 (lung adenocarcinoma); solid stars, H1666 (lung adenocarcinoma); solid half-circles, H2122 (lung adenocarci-
noma). Data are presented as mean 6 SEM of four experiments.
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cell (H226, 1703) versus relatively nonpermissive adeno-
carcinoma (H1437, H2122) cell types. The results of the
1-h binding studies (performed at 48C at an Ad cpm/cell
ratio of 3) demonstrate that the squamous cell cancers
bind more vector than do the adenocarcinoma cells (Fig-
ure 2). Moreover, excess fiber knob (10 mg/ml; greater
than 1,000-fold excess of Ad particles/cell) inhibits Ad
binding in the squamous cell cancers, but does not appear
to impact Ad binding to the adenocarcinoma cells. These
results suggest that binding to the permissive cells is occur-
ring via a specific cell–Ad fiber knob interaction, and by a
different, nonspecific binding mechanism in the transduc-
tion-refractory cell types. Thus, these results indicate that
differences in adenoviral binding may contribute to differ-
ences in the transduction efficiencies of individual cell
lines.
In a separate series of experiments, the kinetics of Ad
entry into a squamous cell cancer (H226) and an adeno-
carcinoma (H1437) cell line were compared. As shown in
Figure 3A, the squamous cell cancer line H226 binds (at
48C) significantly more vector at all time points than the
adenocarcinoma cell line (H1437). Both cell types bind
more vector over time, and the absolute quantity of ade-
novirus bound by the squamous cell cancer at 0.75 h is
roughly equivalent to that bound by the adenocarcinoma
at 10 h. The efficiently transduced squamous cell cancer
line also internalizes more vector at all time points than
the adenocarcinoma cell line (Figure 3B). The kinetics of
viral entry into the permissive cells can be described by a
fast linear component that appears to saturate following
the 10-h time point. In contrast, the internalization of 35S-
Ad vector into the adenocarcinoma cell line is linear and
significantly slower at each time point compared to the
squamous cell cancer. The efficiency of internalization of
bound vector (i.e., percentage internalized divided by
bound plus cell surface-associated 35S-Ad vector) was de-
termined 0.75 h following adenoviral exposure (in an ef-
fort to minimize the role of receptor recycling), and is very
high (100%) for the squamous cell cancer line in contrast
to the adenocarcinoma cell line (, 20%). These data indi-
cate that Ad internalization is more efficient for the H226
than the H1437 cell line, and also contributes to relative
disparity of gene transfer efficiency into these subtypes.
It is notable that internalization of Ad into all target
cells increases with prolonged exposure to the virus (Fig-
ure 3B). The data show that the quantity of Ad internalized
by the transduction-refractory H1437 cell line at 30 h ap-
proximates that internalized by the transduction-sensitive
H226 cell line by 3 h, suggesting that the relative ineffi-
ciency of transduction of the lung adenocarcinoma cell
lines may be overcome by prolonging the exposure of the
vector to the target cells. To test this hypothesis, adenovi-
ral vectors were exposed to the squamous cell (H226) and
adenocarcinoma (H1437 and H2122) cell lines at an MOI
of 50 for various time intervals ranging from 0.75 to 24 h.
As predicted, whereas the squamous cell cancer is rapidly
and efficiently transduced, prolonging the duration of ex-
posure to the adenoviral vector permits transduction of
the adenocarcinoma cell lines (Figure 4). Indeed, a 24-h
exposure of the vector to the most transduction-resistant
lung adenocarcinoma studied (H2122) results in nearly
uniform cellular transduction.
Transduction efficiencies of NSCLC cell lines were also
investigated using the amphotropic retroviral vector. The
range of MOIs tested is limited for the amphotropic RV
vector because of the difficulty in concentrating this vector
Figure 3. (A) Comparison of adenoviral binding to a squamous
cell line (open squares, H226) versus a lung adenocarcinoma cell
line (solid squares, H1437) as a function of time. At 48C, target
cells were exposed to radiolabeled adenoviral vector, and the
percentage bound vector quantified over time. Data are pre-
sented as mean 6 SEM of 35S radiocounts from six samples at
each time point. (B) Comparison of adenoviral internalization
into a squamous cell line (open squares, H226) versus an adeno-
carcinoma cell line (solid squares, H1437) as a function of time.
At 378C, target cells were exposed to radiolabeled adenoviral
vector, and the percentage internalized vector quantified over
time. Data are presented as mean 6 SEM of radiocounts from
four samples at each time point. *P , 0.001 by the unpaired two-
tailed t test for a statistically significant difference between the
two groups at various times.
Figure 2. Comparison of adenoviral binding to transduction-sen-
sitive squamous cell cancer cells (H226, H1703; open bars) versus
transduction-resistant adenocarcinoma cells (H1437, H2122;
shaded bars). Radiolabeled Ad is exposed to target cells at 48C in
the absence or presence of 10 mg/ml adenoviral fiber knob for 1 h,
and cell-bound vector counted. Data are presented as mean 6
SEM of 35S radiocounts from three separate samples at each time
point. *P , 0.001 by ANOVA on ranks followed by Bonferroni
group comparisons for a statistically significant difference be-
tween groups.
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to titers comparable with the Ad vectors. In contrast to the
data for Ad vectors, adenocarcinoma (H1437) is trans-
duced with significantly greater efficiency by the retroviral
vector than the squamous cell cancer (H226) and mesothe-
lioma (H28) cell lines (Figure 5A). The RV vectors reli-
ably transduced 25–50% of the H1437 adenocarcinoma
cells at MOIs of 1–5, whereas an adenoviral MOI of 100–
1,000 is required to transduce the H1437 cells with compa-
rable efficiency (Figures 1A and 1C). To determine whether
the H1437 cell line is representative of other NSCLC ade-
nocarcinomas, a panel of adenocarcinoma cell lines (H441,
H1437, H1650, H1666, and H2122) was exposed to the am-
photropic RV LNPOZ. A range of transduction efficien-
cies was noted for this NSCLC subtype (Figure 5B). For
example, of the adenocarcinoma cell lines studied, the
H1437 and H2122 cell lines are transduced with signifi-
cantly greater efficiency than the H1650 and H1666 cell
lines, and H441 (alveolar cell cancer) is relatively resistant
to retroviral transduction. Therefore, it is unclear whether
RV transduces in a “subtype-specific” pattern.
We investigated two variables that may contribute to
RV transduction efficiency. First, because Mo-MuLV-
based retroviral vectors transduce only dividing cells, we
determined the proliferation status of the tumor cell lines.
The results (Table 1) indicate that the proliferative frac-
tions (as defined by BrdU positivity) among the target tu-
mor cell populations are similar, suggesting that variability
in RV transduction cannot be ascribed simply to differ-
ences in proliferation rates. Second, we postulated that
differences in transduction efficiency might reflect differ-
ences in RV binding/entry into the target cells. To study
one component of RV entry, we measured amphotropic
retroviral receptor (RAM-1) expression by Northern anal-
ysis in permissive (H1437 and H2122) and relatively non-
permissive (H226 and H441) cell lines. Both the permissive
and relatively nonpermissive cell lines express detectable
RAM-1 mRNA levels (Figure 6), suggesting that the dis-
parate RV transduction efficiencies in these NSCLC cell
lines are due to properties other than the steady state ex-
pression of receptor mRNA.
Discussion
Efficient in vivo gene transfer is a prerequisite for success-
ful gene therapy for lung cancer. Currently, the most effi-
cient gene transfer vehicles appear to be viral vectors. In
this study, we sought to identify which viral vector would
be optimal for targeting lung cancer by testing adenoviral
and retroviral vectors in a spectrum of NSCLC subtypes.
Adenoviral vectors most efficiently transduce squamous
cell cancer lines, whereas adenocarcinoma and large cell
cancer cell lines are relatively resistant to adenoviral trans-
duction (Figures 1A through 1C). Although some variabil-
ity exists in the transduction efficiencies between different
cell lines of the same subtype, the NSCLC adenocarci-
noma cell lines are generally more resistant to adenoviral
transduction than squamous cell cancer lines (Figures 1B
and 1C). However, the relative resistance to Ad transduc-
tion of the adenocarcinoma cell lines can be overcome by
using high titers of the adenoviral vectors (Figure 1C).
Next, we studied the mechanisms that explain the range
of transduction efficiencies observed using radiolabeled
vectors to study adenoviral–target cell interactions. In the
Ad-resistant adenocarcinoma cell lines H1437 and H2122,
reductions in both the specific binding (Figures 2 and 3A)
and internalization (Figure 3B) of the adenoviral vector
are observed as compared with the transduction-sensitive
squamous cell cancer lines H226 and H1703. The effi-
ciency of entry of bound vectors was calculated and found
to be greater for the H226 squamous cell line (100%) than
for the H1437 adenocarcinoma cell line (, 20%). Taken
together, these findings suggest that the resistance to Ad
gene transfer reflects reduced numbers of receptors and/or
less efficient mechanisms mediating Ad binding and inter-
nalization.
Figures 3A and 3B demonstrate that Ad binding and
internalization into NSCLC adenocarcinoma cells in-
creases over time, suggesting that transduction efficiency
can be enhanced by prolonging the duration of exposure
to the vector. Indeed, in addition to increasing the MOI
(Figure 1C), Ad transduction is increased at lower MOIs
by prolonging incubation of the vector with the target cell
(Figure 5). This observation may have relevance to our ap-
proach of targeting tumor in malignant pleural effusions,
because the pathogenesis of these effusions is rooted in the
lack of lymphatic clearance of the pleural space. Hence, in
this setting, clearance of vector delivered into the pleural
space will likely be limited, enabling prolonged interaction
Figure 4. Comparison of the kinetics of Ad transduction of a
squamous cell line (open squares, H226) versus lung adenocarci-
noma cell lines (solid squares, H1437; solid half-circles, H2122) as
a function of time. Equal numbers of target cells were exposed to
the lacZ adenoviral vector at an MOI of 50 for 0.75, 3, 6, 12, or
24 h, and transduction efficiency (expression of b-galactosidase)
measured 24 h later by flow cytometry. Data are presented as
mean 6 SEM of three separate experiments. By probit analysis, a
statistically significant (P , 0.05) difference exists between the
curves with H226 . H1437 . H2122 in terms of expediency of Ad
transduction.
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with the target cells and consequently optimizing the chances
for transduction. Preliminary studies using an in vivo intra-
cavitary model of lung adenocarcinoma suggest that H1437
cells can be readily transduced at low MOIs (1 to 10) in
vivo, probably because in this model the vector is not cleared
from the vicinity of the target cell.
Similar to the adenoviral vector, the retroviral vector
transduces NSCLC subtypes in vitro (Figure 5A) with a
wide range of transduction efficiencies. In fact, substantial
variability is observed within a single histopathologic sub-
type (Figure 5B). Indexed to MOI, the data in general sug-
gest that the amphotropic retroviral vector may be more
efficient at transducing NSCLC adenocarcinoma cells than
the adenoviral vector (Figure 5 versus Figure 1). Unfortu-
nately, the inability to generate high-titer amphotropic ret-
roviral vector makes it impossible to compare directly RV
transduction over the ranges of MOI studied for the aden-
oviral vector.
We have studied two of the steps in the RV transduc-
tion scheme to identify the rate-limiting parameters that
contribute to the diversity of transduction efficiencies ex-
hibited by these vectors. First, the transduction efficiency
is not a function of the proliferative rates of the target cells
and all cell lines exhibited approximately equal replicating
fractions (Table 1). Second, to explore the hypothesis that
the variability reflects differences in retroviral entry, we
measured the steady state expression levels of the mRNA
for the amphotropic retroviral cell surface receptor (RAM-1)
in permissive and relatively nonpermissive cell types. We
found that both permissive and nonpermissive NSCLC cell
types express RAM-1 by Northern analysis (Figure 6), sug-
gesting that although expression of the receptor is proba-
bly required, it is not sufficient to mediate efficient trans-
duction. Assuming that the steady state RAM-1 mRNA
levels reflect functional cellular RV binding receptor num-
bers, these results suggest that the differences in the RV
transduction efficiencies may be attributable to cellular pro-
cessing of the vector after binding/entry. These data are
congruent with those generated by others at this center re-
garding RV entry into well-differentiated versus poorly
differentiated airway epithelial cell cultures, and suggest
that reduced RV transduction of well-differentiated air-
way epithelia is not secondary to cellular turnover, but rather
is a function of reduced RV adherence and internalization,
and/or reduced reverse transcription of the vector follow-
ing entry (37).
In conclusion, these in vivo studies were undertaken to
characterize the efficiencies of vector targeting of lung
cancer cells metastatic to the pleural space. With both viral
vectors studied, we observed substantial variability in the
TABLE 1
Non-small cell or mesothelial derivation of the
various cell lines used in this study
Cell Line Derivation % BrdU1*
H28 Malignant mesothelioma 46 6 6
H157 Squamous cell lung cancer
H226 Squamous cell lung cancer 45 6 4
H441 Lung adenocarcinoma
H460 Large cell lung cancer 53 6 4
H647 Adenosquamous lung cancer 40 6 9
H1437 Lung adenocarcinoma 49 6 3
H1650 Lung adenocarcinoma
H1666 Lung adenocarcinoma
H1703 Squamous cell lung cancer
H2122 Lung adenocarcinoma
Mv1Lu Mink lung epithelium 53 6 4
* The fraction of cells proliferating (% BrdU1) over the time course of ret-
roviral transduction is presented as the mean 6 SEM of three separate mea-
surements for several subtypes.
Figure 5. (A) Comparison of am-
photropic retroviral transduction
of NSCLC subtypes, malignant
mesothelioma, or Mv1Lu cells as
a function of MOI. Target cells
were exposed to a lacZ amphotro-
pic retroviral vector at various
MOIs for 2 h, and transduction ef-
ficiency (expression of b-galac-
tosidase) measured 48 h later by
flow cytometry. Open diamonds,
Mv1Lu cells (a mink lung epithe-
lial cell line that is highly trans-
ducible with these vectors); open
circles, H28 (malignant mesothe-
lioma); open squares, H226 (squa-
mous cell carcinoma); open trian-
gles, H460 (large cell lung cancer);
open stars, H647 (adenosquamous
lung cancer); solid squares, H1437
(lung adenocarcinoma). (B) Com-
parison of amphotropic RV transduction of various NSCLC adenocarcinomas as a function of MOI. Target cells were exposed to a lacZ
amphotropic retroviral vector at various MOIs for 2 h, and transduction efficiency measured 48 h later by expression of b-galactosidase
using flow cytometry. Solid circles, H441 (lung adenocarcinoma); solid squares, H1437 (lung adenocarcinoma); solid triangles, H1650
(lung adenocarcinoma); solid stars, H1666 (lung adenocarcinoma); solid half-circles, H2122 (lung adenocarcinoma). Data are presented
as mean 6 SEM of four experiments.
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transduction efficiencies of cancer cells derived from dif-
ferent and even the same histopathologic subtypes of lung
cancer. With respect to the adenoviral vector, the differ-
ences in transduction are in part due to the binding and
rate of entry into the target cells, and resistance to adeno-
viral transduction may be overcome by increasing the MOI
or by prolonging the duration of the vector to the target
cells. With respect to the retroviral vectors, although they
may be more efficient vehicles for transducing NSCLC ad-
enocarcinomas than the adenoviral vectors in vitro, we have
not been able to identify specific processes that predict gene
transfer efficacy.
Given the limited numbers of cell lines tested, these re-
sults do not enable us to generalize our observations uni-
versally to all cultured NSCLCs, and because the expres-
sion and distribution of receptors mediating vector entry
in tumor are largely unknown, we cannot make predic-
tions regarding the in vivo transduction of NSCLC. There
is a paucity of data correlating the behavior of vector–tar-
get cell interactions, and therefore gene transfer effi-
ciency, in vitro as compared with in vivo, and more impor-
tantly, in situ. Consequently, it is clear that additional
studies using the Ad and RV vectors in in vivo model sys-
tems that aptly mimic the human disease are needed be-
fore the optimal vector(s) for gene therapy of NSCLC can
be resolved.
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